NCT06191354View on ClinicalTrials.gov

A Clinical Study Evaluating the Safety and Efficacy of SKG0201 Injection in Patients With Spinal Muscular Atrophy Type 1

NARecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 25, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions
Spinal Muscular Atrophy 1
Interventions
GENETIC

SKG0201 Injection

SKG0201 is a recombinant adeno-associated virus (rAAV) vector-based in vivo gene therapeutic product.

Trial Locations (3)

200092

RECRUITING

Xinhua Hospital Affiliated To Shanghai Jiao Tong University School Of Medicine, Shanghai

Unknown

RECRUITING

West China Sencond Hospital, Sichuan University / West China women's and children's Hospital, Chengdu

NOT_YET_RECRUITING

National Children's Medical Center, Children's Hospital of Fudan University, Shanghai

All Listed Sponsors
lead

Kun Sun

OTHER